5/9/2025

Janusmed sex and gender

Janusmed sex and gender – roflumilast

Janusmed Sex and Gender is a knowledge database providing information on sex and gender aspects of drug treatment. The knowledge database is primarily intended to be used by physicians and healthcare professionals. The texts are general and should not be considered as treatment guidelines. The individual patient’s physician is responsible for the patient’s drug treatment.

Back to index
C C
C C

Roflumilast

Roflumilast

Class : C

Show all info

Print

Contact us

  1. Daliresp (roflumilast). DailyMed [www]. US National Library of Medicine. [updated 2018-01-23, cited 2019-08-29].

  2. Daxas (roflumilast). Summary of Product Characteristics. European Medicines Agency (EMA) [cited 2019-05-28, updated 2018-04-25],

  3. Huang J, Fu CX, Yang XY, Cui C, Yang S, Kuang Y et al. Pharmacokinetics of single- and multiple-dose roflumilast: an open-label, three-way crossover study in healthy Chinese volunteers. Drug Des Devel Ther. 2018;12(1):4047-4057.

  4. Lahu G, Hünnemeyer A, Diletti E, Elmlinger M, Ruth P, Zech K et al. Population pharmacokinetic modelling of roflumilast and roflumilast N-oxide by total phosphodiesterase-4 inhibitory activity and development of a population pharmacodynamic-adverse event model. Clin Pharmacokinet. 2010;49(9):589-606.

  5. Fabbri LM, Calverley PM, Izquierdo-Alonso JL, Bundschuh DS, Brose M, Martinez FJ et al. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet. 2009;374(9691):695-703.

  6. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2018 [cited 2019-05-28.]

  1. Daliresp (roflumilast). DailyMed [www]. US National Library of Medicine. [updated 2018-01-23, cited 2019-08-29].
  2. Daxas (roflumilast). Summary of Product Characteristics. European Medicines Agency (EMA) [cited 2019-05-28, updated 2018-04-25],
  3. Huang J, Fu CX, Yang XY, Cui C, Yang S, Kuang Y et al. Pharmacokinetics of single- and multiple-dose roflumilast: an open-label, three-way crossover study in healthy Chinese volunteers. Drug Des Devel Ther. 2018;12(1):4047-4057.
  4. Lahu G, Hünnemeyer A, Diletti E, Elmlinger M, Ruth P, Zech K et al. Population pharmacokinetic modelling of roflumilast and roflumilast N-oxide by total phosphodiesterase-4 inhibitory activity and development of a population pharmacodynamic-adverse event model. Clin Pharmacokinet. 2010;49(9):589-606.
  5. Fabbri LM, Calverley PM, Izquierdo-Alonso JL, Bundschuh DS, Brose M, Martinez FJ et al. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet. 2009;374(9691):695-703.
  6. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2018 [cited 2019-05-28.]